Media Thread, page-17045

I guess, just my prediction,

1. Imugene are aiming for "Breakthrough Therapy Designation" from the FDA or TGA (Australia) for azercell
2. Acceleration of Phase 2 trials with larger cohorts for vaxinia
3. garner/ already have Interest from biopharma for co-development or licensing agreements for Oncarlytics, if targetless tumors just converts into treatable tagets (this will blockbuster)
4. The most controversial and shorters claim and RACs favourite kid, potential announcement of new funding rounds or partnerships to support expanding trials.
5. Additional patents granted for CF33 and other pipeline assets in key regions
6. The holy grail , potential licensing deals or acquisitions by larger pharma companies

All this can happen as soon as 2025, any one of these will have a major upside...